10-Q: Movano Inc. Reports Second Quarter 2024 Results, Highlights Progress on Evie Ring and FDA Submissions

Movano Inc. reported its financial results for the second quarter of 2024, noting a net loss but also highlighting progress in product development and regulatory submissions.

Summary

• Movano Inc., a technology company focused on healthcare solutions, released its financial results for the quarter ended June 30, 2024.
• The company reported a net loss of $6.2 million for the three months ended June 30, 2024, compared to a net loss of $7.3 million for the same period in 2023.
• For the six months ended June 30, 2024, the net loss was $11.9 million, compared to $14.4 million for the same period in 2023.
• Revenue for the six months ended June 30, 2024 was $0.9 million, primarily from the sale of the Evie Ring, while there was no revenue in the same period of 2023.
• The company's cash and cash equivalents totaled $16.9 million as of June 30, 2024.
• Movano used $12.3 million in operating activities during the first six months of 2024.
• The company raised $24.1 million in gross proceeds from a private placement in April 2024.
• Movano is developing the Evie Ring, a wearable device for women, and is also working on FDA clearances for its medical device version, EvieMED.
• The company is also developing a System-on-a-Chip (SoC) for blood pressure and continuous glucose monitoring.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in product development and regulatory submissions, the company is still incurring significant losses and faces challenges in funding its operations. The material weakness in internal controls is also a concern.

Positives

• The company's net loss decreased year-over-year for both the three and six month periods ending June 30, 2024.
• Movano generated $0.9 million in revenue in the first six months of 2024, primarily from the Evie Ring.
• The company successfully raised $24.1 million through a private placement in April 2024.
• Movano re-submitted its 510(k) application to the FDA for the EvieMED Ring's pulse oximeter.
• The company is actively conducting clinical trials for its innovative System-on-a-Chip (SoC) technology.

Negatives

• Movano continues to incur net losses, with a loss of $6.2 million for the three months ended June 30, 2024.
• The company has an accumulated deficit of $136.3 million as of June 30, 2024.
• Movano's cash and cash equivalents are not expected to be sufficient to fund operations for the next twelve months.
• The company's disclosure controls and procedures were deemed ineffective as of June 30, 2024, due to a material weakness in internal controls over financial reporting.
• Customer refunds and returns offset revenue recognition in the second quarter of 2024.

Risks

• Movano has a limited operating history and may not achieve profitability.
• The company's ability to continue as a going concern is dependent on securing additional capital.
• There is a risk that the company may not be able to successfully develop and commercialize its products.
• Movano is dependent on third parties for manufacturing, marketing, and distribution.
• The company faces competition from other products and technologies.
• The company needs to secure regulatory approvals from the FDA and other governmental authorities.
• There is a risk of dilution for stockholders if the company raises additional funds through equity offerings.
• The company has identified a material weakness in its internal control over financial reporting.

Future Outlook

Movano expects to continue to incur significant expenses and increasing operating losses for at least the next several years, and will need to raise additional capital to fund its operations.

Management Comments

• Management believes that FDA clearance of the EvieMED metrics would foster clinical-level confidence in its monitoring capabilities.
• Management is working with the FDA to address the review commentary on the 510(k) submission.
• Management expects to finance future cash needs through public or private equity offerings, debt financings or corporate collaborations and licensing arrangements.

Industry Context

Movano is operating in the growing market of wearable health technology, competing with companies that offer similar devices for health and wellness monitoring. The company is differentiating itself by focusing on women's health and seeking FDA clearances for its medical device version, EvieMED.

Comparison to Industry Standards

• Movano's revenue of $0.9 million for the first six months of 2024 is relatively low compared to established wearable technology companies like Fitbit (now part of Google) or Apple, which generate billions in revenue annually.
• The company's net loss of $11.9 million for the first six months of 2024 is typical for an early-stage technology company investing heavily in research and development, but it is important to compare this to other companies in the same stage of development.
• Movano's focus on FDA clearance for its medical device version, EvieMED, is a strategic move to differentiate itself from competitors that primarily focus on general wellness devices. This approach is similar to companies like Dexcom in the continuous glucose monitoring space, which have achieved significant market success with FDA-cleared devices.
• The company's development of a proprietary System-on-a-Chip (SoC) for blood pressure and glucose monitoring is a significant technological undertaking, and its success will be crucial for its long-term competitiveness. This is similar to companies like AliveCor, which have developed proprietary technology for ECG monitoring.

Related Party Transactions

• Certain directors and officers participated in the April 2024 private placement, purchasing 287,500 units at an offering price of $0.565 per share.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional funds through equity offerings.
• Employees may be affected by potential cost-cutting measures if the company faces financial difficulties.
• Customers may benefit from the development of new and innovative health monitoring devices.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Movano will continue to work with the FDA on its 510(k) submission for the EvieMED Ring.
• The company will continue to conduct clinical trials for its System-on-a-Chip (SoC) technology.
• Movano will seek additional financing to fund its future operations.
• The company will work to remediate the material weakness in its internal control over financial reporting.

Key Dates

Keywords

wearable technology, Evie Ring, EvieMED, FDA clearance, medical devices, healthcare, pulse oximeter, blood pressure monitoring, glucose monitoring, System-on-a-Chip, clinical trials, financial results, private placement, capital raise